中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2017, 29(9): 855-863
人γδ T细胞的抗肿瘤临床免疫治疗新进展
谈思怡1,3,向 征2,徐 艳1,吴扬哲1*,尹芝南1*
(1 暨南大学生物医学转化研究院及附属第一医院,广州 510632;2 香港大学李嘉诚医学院儿童及青少年科学系,转化免疫学实验室,香港;3 中山大学肿瘤防治中心生物治疗中心,广州 510060)
摘 要:γδ T 细胞自发现30 余年来,其研究较其他免疫细胞相对滞后,甚至被认为是进化的“残留物(relics)”。但越来越多的研究显示,γδ T 细胞在人的免疫功能中发挥着非常重要的作用,是天然免疫与获得性免疫的“桥梁”。近年来,γδ T 细胞的抗肿瘤、抗感染的相关研究表明了γδ T 细胞在肿瘤免疫与感染免疫中具有重要功能和临床应用价值。Vγ9Vδ2 亚群是只存在于外周血的一类人γδ T 细胞,其数量虽少,但其功能全面、强大。相比肿瘤或传染病患者自体γδ T 细胞的功能被抑制或“后天不足”,健康人来源的同种异体γδ T 细胞由于功能健康,其临床应用价值更具优势。现以抗肿瘤应用为落脚点,综述人γδ T 细胞的生物学功能,识别肿瘤细胞的分子免疫机制,并简单总结国际上自体γδ T 细胞抗肿瘤的应用进展;同时,简述国际上最新关于同种异体γδ T 细胞在抗肿瘤方面的应用动态,并介绍了笔者团队同种异体γδ T 细胞治疗肿瘤的进展概况。
 
Recent progress on human γδ T cells based tumor immunotherapy
TAN Si-Yi1,3, XIANG Zheng2, XU Yan1, WU Yang-Zhe1*, YIN Zhi-Nan1*
(1 Biomedical Translational Research Institute, The First Affiliated Hospital, Jinan University, Guangzhou 510632, China; 2 Li Ka Shing Faculty of Medicine, Department of Paediatrics and Adolescent Medicine, Laboratory for Translational Immunology, University of Hong Kong, Hong Kong SAR; 3 Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China)
Abstract: Human γδ T cells have been treated as evolutionary relics for a long time since the discovery in 1986. Therefore, people paid much less attention to this specific group of T lymphycytes than other types of immune cells. However, increasing reports showed that γδ T cells play many important roles in human immune responses, and “bridge” between innate immunity and acquired immunity. Among several subsets of γδ T cells, Vγ9Vδ2 subset only represents in peripheral blood of human and primates. Although the small population in T lymphocytes, investigations on this group of γδ T cells during the past a few years revealed that they directly involve in both antitumor and anti-infections, and that they can be applied in clinical treatment of tumor and infection using adoptive infusion. In this review, focused on anti-tumor application of γδ T cells, we discussed the immunological function of γδ T cells, and the molecular mechanism of how γδ T cells recognize cancer cells. Then, we summarized literature reports on using autologous γδ T cells in tumor immunotherapy. In the end, we briefly reviewed the latest international progess on allogenic γδ T cells in anti-tumor research, and then we presented the work progess of our own group on research and development of allogenic γδ T cells in anti-tumor and anti-infection.
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2990294 位访问者,欢迎!